Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (551-560 of 869) with videos related to

Pageof 87
Sort By:
Molecular Cancer Therapeutics|January 17, 2012
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myelomaDouglas W McMillin, Hannah M Jacobs, Jake E Delmore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 ExpressionLijie Xing, Su Wang, Jiye Liu, et al.
Blood Cancer Journal|February 3, 2023
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeuticsDaisuke Ogiya, Zuzana Chyra, Sigitas J Verselis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2019
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple MyelomaClaire Fabre, Naoya Mimura, Kathryn Bobb, et al.
Cancer Cell|October 6, 2009
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic targetDharminder Chauhan, Ajita V Singh, Mohan Brahmandam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaClaire Fabre, Naoya Mimura, Kathryn Bobb, et al.
Blood|January 24, 2012
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantationMelinda A Biernacki, Yu-tzu Tai, Guang Lan Zhang, et al.
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 29, 2014
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory CommitteeNoopur Raje, Beth Faiman, R Donald Harvey, et al.
Blood|January 5, 2013
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemiaIrene M Ghobrial, Federico Campigotto, Timothy J Murphy, et al.
Pageof 87

Showing results (551-560 of 869) with videos related to

Sort By:
Pageof 87
Molecular Cancer Therapeutics|January 17, 2012
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myelomaDouglas W McMillin, Hannah M Jacobs, Jake E Delmore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 ExpressionLijie Xing, Su Wang, Jiye Liu, et al.
Blood Cancer Journal|February 3, 2023
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeuticsDaisuke Ogiya, Zuzana Chyra, Sigitas J Verselis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2019
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple MyelomaClaire Fabre, Naoya Mimura, Kathryn Bobb, et al.
Cancer Cell|October 6, 2009
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic targetDharminder Chauhan, Ajita V Singh, Mohan Brahmandam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaClaire Fabre, Naoya Mimura, Kathryn Bobb, et al.
Blood|January 24, 2012
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantationMelinda A Biernacki, Yu-tzu Tai, Guang Lan Zhang, et al.
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 29, 2014
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory CommitteeNoopur Raje, Beth Faiman, R Donald Harvey, et al.
Blood|January 5, 2013
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemiaIrene M Ghobrial, Federico Campigotto, Timothy J Murphy, et al.
Pageof 87